|
| Demonstrated effect/mechanism | Host | Ref. |
|
Probiotic mixtures | | | |
|
BIFICO mixture | Prevention of flare-ups of chronic ulcerative colitis/inhibition of NF-κB activation, decrease the expressions of TNF-α and IL-1β and increased expression of IL-10 | Patients with UC | [65] |
|
VSL#3 mixture | Prevention of autoimmune diabetes/increased production of IL-10 from Peyer's patches and the spleen, increased IL-10 expression in the pancreas | Nonobese diabetic mice | [66] |
|
| Antiallergic effect/cytokine production by spleen cells was modulated towards a Treg/Th0 profile, increased IL-10 and IFN-γ production, reduction of serum specific IgG1, reduction of IL-13 and IL-4 mRNA expression, and increased IL-10 expression at lung level | Allergen-induced mice | [67] |
|
| Improvement of colitis/increased production of IL-10 and number of regulatory CD4+ T cells bearing surface TGF-βa in the form of latency-associated protein | TNBS-induced mice | [68] |
|
L. paracasei DSM 13434, L. plantarum DSM 15312 & 15313 | Decreased autoimmune encephalomyelitis/attenuation of proinflammatory Th1 and Th17 cytokines followed by IL-10 induction in mesenteric lymph nodes, and involvement of IL-10 producing CD4(+)CD25(+) Treg cells | Multiple sclerosis mice | [69] |
|
Fermented products | | | |
|
Probiotic yogurt | Inhibition of colon tumour growth/decrease of the inflammatory response by increasing IL-10-secreting cells, cellular apoptosis, and diminishing procarcinogenic enzymes | DMH-induce mice | [70] |
|
| Reduction of the severity of intestinal inflammation/increased levels of IL-10 in the intestines and decrease in IL-17 and IL-12 levels in addition to beneficial changes in the intestinal microbiota | TNBS-induced mice | [46] |
|
Fermented Maesil (Prunus mume) with probiotics | Suppression of the development of atopic dermatitis-like skin lesions/increased serum concentration of IL-10 and decreased IL-4, decreases in eosinophil ratio and serum IgE concentration | NC/Nga mouse model | [71] |
|
Probiotic strains | | | |
|
L. casei DG | Improvement of gut microbiota/reduction of TLR4 and IL-1β mRNA levels and significantly increased mucosal IL-10 | Patients with UC | [72] |
|
L. casei CRL 431 | Increased resistance against Streptococcus pneumonia/improved production of TNF-α and activity of phagocytes in the respiratory tract, IL-4 and IL-10 were significantly increased, increase in the levels of specific respiratory IgA | Malnourished mice | [73] |
|
L. rhamnosus GG | Amelioration of intestinal inflammation/decreased LPS-induced cytokine-induced neutrophil chemoattractant-1 production in liver and plasma, meliorated LPS-suppressed IL-10 level in lungs and decreased IL-1b production in liver | Gastrostomy-fed rats | [74] |
|
L. casei BL23 | Protection against colitis/increased IL-10/IL-12 cytokine ratio | TNBS-induced mice | [75] |
|
L. delbrueckii UFV-H2b20 | Protection against L. monocytogenes/induced higher production of IL-10 in the mucosal immune system, favored and effector responses (increased production of TNF-α in the serum, peritoneal cavity, and gut) while preventing their immunopathological consequences | Germ-free mice | [76] |
|
L. salivarius CECT5713 | Improvement of gut microbiota/significant increase of NK cells and monocytes, as well as the plasmatic levels of IgM, A, and G, and the regulatory cytokine IL-10 | Healthy adults | [77] |
|
S. cerevisiae UFMG 905 | Prevention of bacterial translocation and improvement of intestinal barrier integrity/increase of IL-10 levels | Murine intestinal obstruction model | [78] |
|
L. casei DN-114 001 | Prevention of induced colitis/increase in TGF-β and IL-10 mRNA and protein expression | DSS-induced mice | [54] |
|
GM-strains | | | |
|
L. plantarum NCIMB8826ΔDlt | Immunomodulatory properties/reduction of secretion of proinflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-8), and increase in IL-10 production | TNBS-induced mice | [79] |
|
L. lactis IL-10 | Prevention of pulmonary inflammation and mucus hypersecretion. Decrease in eosinophil numbers, EPO activity, anti-OVA IgE, and IgG1 levels, IL-4, IL-5, CCL2, CCL3, CCL5, and CCL11 | OVA-induced mice | [80] |
|
| Reduction in colitis and histological damages of the intestines/increased IL-10 levels in the intestines | DSS-induced mice | [81] |
|